Pacer Advisors, Inc. Immuno Gen, Inc. Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 21, 2021	SELL	$5.79 - $8.6 $51,218 - $76,075	-8,846 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$6.5 - $10.53 $15,860 - $25,693	-2,440 Reduced 21.62%	8,846 $72,000
Q4 2020 Jan 20, 2021	BUY	$3.7 - $7.66 $547 - $1,133	148 Added 1.33%	11,286 $73,000
Q3 2020 Oct 19, 2020	BUY	$3.45 - $4.89 $38,426 - $54,464	11,138 New	11,138 $40,000
Q4 2018 Feb 13, 2019	SELL	$3.94 - $9.7 $88,728 - $218,443	-22,520 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $193,672 - $253,575	22,520 New	22,520 $213,000
Q1 2018 May 14, 2018	SELL	$6.7 - $12.95 $43,764 - $84,589	-6,532 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $33,117 - $51,733	6,532	6,532 $42,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.